Influence of Appropriate Empirical Antibiotic Treatment on the Prognosis of ICU Patients with HAP Caused by Carbapenem-Resistant Gram-Negative Bacteria

References

• Kollef MH, Torres A, Shorr AF, Martin-Loeches I, Micek ST. Nosocomial infection. Crit Care Med. 2021;49(2):169–187. doi:10.1097/ccm.0000000000004783
   PubMed Web of Science ®Google Scholar
• Zhou Y, Yu F, Yu Y, Zhang Y, Jiang Y. Clinical significance of MDRO screening and infection risk factor analysis in the ICU. Am J Transl Res. 2021;13(4):3717–3723.
   PubMed Web of Science ®Google Scholar
• Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304–377. doi:10.1007/s00134-017-4683-6
   PubMed Web of Science ®Google Scholar
• Kaye KS, Pogue JM. Infections Caused by Resistant Gram-Negative Bacteria: epidemiology and Management. Pharmacotherapy. 2015;35(10):949–962. doi:10.1002/phar.1636
   PubMed Web of Science ®Google Scholar
• Maechler F, Peña Diaz LA, Schröder C, Geffers C, Behnke M, Gastmeier P. Prevalence of carbapenem-resistant organisms and other Gram-negative MDRO in German ICUs: first results from the national nosocomial infection surveillance system (KISS). Infection. 2015;43(2):163–168. doi:10.1007/s15010-014-0701-6
   PubMed Web of Science ®Google Scholar
• Furuya EY, Cohen B, Jia H, Larson EL. Long-Term Impact of Universal Contact Precautions on Rates of Multidrug-Resistant Organisms in ICUs: a Comparative Effectiveness Study. Infect Control Hospital Epidemiol. 2018;39(5):534–540. doi:10.1017/ice.2018.35
   PubMed Web of Science ®Google Scholar
• Santella B, Serretiello E, De Filippis A, et al. Lower Respiratory Tract Pathogens and Their Antimicrobial Susceptibility Pattern: a 5-Year Study. Antibiotics. 2021;10(7):465. doi:10.3390/antibiotics10070851
   Google Scholar
• Pop-Vicas AE, D’Agata EM. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin Infect Dis. 2005;40(12):1792–1798. doi:10.1086/430314
   PubMed Web of Science ®Google Scholar
• Teixeira PJ, Seligman R, Hertz FT, Cruz DB, Fachel JM. Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes. J Hosp Infect. 2007;65(4):361–367. doi:10.1016/j.jhin.2006.12.019
   PubMed Web of Science ®Google Scholar
• Zak-Doron Y, Dishon Benattar Y, Pfeffer I, et al. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: a Prospective Study. Clin Infect Dis. 2018;67(12):1815–1823. doi:10.1093/cid/ciy371
   PubMed Web of Science ®Google Scholar
• Li R, Tang H, Xu H, Cui K, Li S, Shen J. Effect on 30-day mortality and duration of hospitalization of empirical antibiotic therapy in CRGNB-infected pneumonia. Ann Clin Microbiol Antimicrob. 2021;20(1):15. doi:10.1186/s12941-021-00421-2
   PubMed Web of Science ®Google Scholar
• Al-Dorzi HM, Asiri AM, Shimemri A, et al. Impact of empirical antimicrobial therapy on the outcome of critically ill patients with Acinetobacter bacteremia. Ann Thorac Med. 2015;10(4):256–262. doi:10.4103/1817-1737.164302
   PubMed Web of Science ®Google Scholar
• Satlin MJ, Cohen N, Ma KC, et al. Bacteremia due to carbapenem-resistant Enterobacteriaceae in neutropenic patients with hematologic malignancies. J Infect. 2016;73(4):336–345. doi:10.1016/j.jinf.2016.07.002
   PubMed Web of Science ®Google Scholar
• Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J. 2017;50(3). doi:10.1183/13993003.00582-2017
   Google Scholar
• Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis. 2021;72(7):e169–e183. doi:10.1093/cid/ciaa1478
   PubMed Web of Science ®Google Scholar
• Hou Y, Ren J, Li J, et al. Relationship Between Mean Vancomycin Trough Concentration and Mortality in Critically Ill Patients: a Multicenter Retrospective Study. Front Pharmacol. 2021;12:690157. doi:10.3389/fphar.2021.690157
   PubMed Web of Science ®Google Scholar
• Ren J, Hou Y, Li J, et al. An evaluation on the association of vancomycin trough concentration with mortality in critically ill patients: a multicenter retrospective study. Clin Transl Sci. 2021;14(5):1780–1790. doi:10.1111/cts.13020
   PubMed Web of Science ®Google Scholar
• Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004;32(11):2183–2190. doi:10.1097/01.ccm.0000145997.10438.28
   PubMed Web of Science ®Google Scholar
• Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063–e1143. doi:10.1097/ccm.0000000000005337
   PubMed Web of Science ®Google Scholar
• Seymour CW, Gesten F, Prescott HC, et al. Time to Treatment and Mortality during Mandated Emergency Care for Sepsis. N Engl J Med. 2017;376(23):2235–2244. doi:10.1056/NEJMoa1703058
   PubMed Web of Science ®Google Scholar
• Carrara E, Pfeffer I, Zusman O, Leibovici L, Paul M. Determinants of inappropriate empirical antibiotic treatment: systematic review and meta-analysis. Int J Antimicrob Agents. 2018;51(4):548–553. doi:10.1016/j.ijantimicag.2017.12.013
   PubMed Web of Science ®Google Scholar
• Chang Y, Jeon K, Lee SM, et al. The Distribution of Multidrug-resistant Microorganisms and Treatment Status of Hospital-acquired Pneumonia/Ventilator-associated Pneumonia in Adult Intensive Care Units: a Prospective Cohort Observational Study. J Korean Med Sci. 2021;36(41):e251. doi:10.3346/jkms.2021.36.e251
   PubMed Web of Science ®Google Scholar
• Morata L, Cobos-Trigueros N, Martínez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2012;56(9):4833–4837. doi:10.1128/aac.00750-12
   PubMed Web of Science ®Google Scholar
• Hernández-Torres A, García-Vázquez E, Gómez J, Canteras M, Ruiz J, Yagüe G. Multidrug and carbapenem-resistant Acinetobacter baumannii infections: factors associated with mortality. Med Clin (Barc). 2012;138(15):650–655. doi:10.1016/j.medcli.2011.06.024
   PubMed Web of Science ®Google Scholar
• Liu CP, Shih SC, Wang NY, et al. Risk factors of mortality in patients with carbapenem-resistant Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect. 2016;49(6):934–940. doi:10.1016/j.jmii.2014.10.006
   PubMedGoogle Scholar
• Zilberberg MD, Nathanson BH, Sulham K, Fan W, Shorr AF. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis. 2017;17(1):279. doi:10.1186/s12879-017-2383-z
   PubMed Web of Science ®Google Scholar
• Lin JN, Chen YH, Chang LL, Lai CH, Lin HL, Lin HH. Clinical characteristics and outcomes of patients with extended-spectrum β-lactamase-producing bacteremias in the emergency department. Intern Emerg Med. 2011;6(6):547–555. doi:10.1007/s11739-011-0707-3
   PubMed Web of Science ®Google Scholar
• Alrstom A, Alsuliman T, Daher N, Abouharb R. The Impact of Modifying Empirical Antibiotic Therapy Based on Intestinal Colonization Status on Clinical Outcomes of Febrile Neutropenic Patients. Infect Chemotherapy. 2021;53(1):63–74. doi:10.3947/ic.2020.0111
   PubMed Web of Science ®Google Scholar
• Katip W, Yoodee J, Uitrakul S, Oberdorfer P. Efficacy of loading dose colistin versus carbapenems for treatment of extended spectrum beta lactamase producing Enterobacteriaceae. Sci Rep. 2021;11(1):18. doi:10.1038/s41598-020-78098-4
   PubMed Web of Science ®Google Scholar
• Lim LM, Ly N, Anderson D, et al. Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy. 2010;30(12):1279–1291. doi:10.1592/phco.30.12.1279
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients. Pharmaceutics. 2021;14(1):31. doi:10.3390/pharmaceutics14010031
   PubMed Web of Science ®Google Scholar
• Stein GE, Babinchak T. Tigecycline: an update. Diagn Microbiol Infect Dis. 2013;75(4):331–336. doi:10.1016/j.diagmicrobio.2012.12.004
   PubMed Web of Science ®Google Scholar
• Grégoire N, Mimoz O, Mégarbane B, et al. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother. 2014;58(12):7324–7330. doi:10.1128/aac.03508-14
   PubMed Web of Science ®Google Scholar
• Katip W, Oberdorfer P. Clinical Efficacy and Nephrotoxicity of Colistin Alone versus Colistin Plus Vancomycin in Critically Ill Patients Infected with Carbapenem-Resistant Acinetobacter baumannii: a Propensity Score-Matched Analysis. Pharmaceutics. 2021;13(2):162. doi:10.3390/pharmaceutics13020162
   PubMed Web of Science ®Google Scholar
• Katip W, Uitrakul S, Oberdorfer P. A Comparison of Colistin versus Colistin Plus Meropenem for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients: a Propensity Score-Matched Analysis. Antibiotics. 2020;9(10):647. doi:10.3390/antibiotics9100647
   Web of Science ®Google Scholar
• Katip W, Oberdorfer P, Kasatpibal N. Effectiveness and Nephrotoxicity of Loading Dose Colistin-Meropenem versus Loading Dose Colistin-Imipenem in the Treatment of Carbapenem-Resistant Acinetobacter baumannii Infection. Pharmaceutics. 2022;14(6):1266. doi:10.3390/pharmaceutics14061266
   PubMed Web of Science ®Google Scholar
• Qian Y, Bi Y, Liu S, Li X, Dong S, Ju M. Predictors of mortality in patients with carbapenem-resistant Klebsiella pneumoniae infection: a meta-analysis and a systematic review. Ann Palliat Med. 2021;10(7):7340–7350. doi:10.21037/apm-21-338
   PubMed Web of Science ®Google Scholar
• Liu Z, Meng Z, Li Y, et al. Prognostic accuracy of the serum lactate level, the SOFA score and the qSOFA score for mortality among adults with Sepsis. Scand J Trauma Resusc Emerg Med. 2019;27(1):51. doi:10.1186/s13049-019-0609-3
   PubMed Web of Science ®Google Scholar
• Soreng K, Levy HR. Procalcitonin: an Emerging Biomarker of Bacterial Sepsis. Clin Microbiol Newsletter. 2011;33(22):171–178. doi:10.1016/j.clinmicnews.2011.10.004
   Google Scholar
• Jekarl DW, Lee S, Kim M, Kim Y, Woo SH, Lee WJ. Procalcitonin as a prognostic marker for sepsis based on SEPSIS-3. J Clin Lab Anal. 2019;33(9):e22996. doi:10.1002/jcla.22996
   PubMed Web of Science ®Google Scholar
• Chaïbi K, Péan de Ponfilly G, Dortet L, Zahar JR, Pilmis B. Empiric Treatment in HAP/VAP: “Don’t You Want to Take a Leap of Faith?”. Antibiotics. 2022;11(3):359. doi:10.3390/antibiotics11030359
   Google Scholar